Anaptys Announces $100 Million Stock Repurchase Plan

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months